·HSK 6

Novo Nordisk
Nuòhé Nuòdé
诺和诺德
and / with
yǔ
与
OpenAI (AI company)
OpenAI
OpenAI
to reach / to conclude
dáchéng
达成
strategic
zhànlüè
战略
partnership / cooperation
hézuò
合作
，
in order to
yǐ
以
artificial intelligence
rén gōng zhìnéng
人工智能
to accelerate
jiāsù
加速
drug / medicine
yàowù
药物
research and development
yán fā
研发
。

Denmark

Dānmài

丹麦

pharmaceutical

zhìyào

制药

giant / major player

jùtóu

巨头

Novo Nordisk

Nuòhé Nuòdé

诺和诺德

with

yǔ

与

OpenAI

on (date marker)

yú

于

April 14th

4 yuè 14 rì

4月14日

to announce

xuānbù

宣布

to reach

dáchéng

达成

strategic

zhànlüè

战略

partnership

hézuò

合作

，

to cover / to encompass

hángài

涵盖

drug / medicine

yàowù

药物

research and development

yán fā

研发

、

manufacturing / production

shēngchǎn

生产

and / as well as

jí

及

commercial / business

shāngyè

商业

operations

yùnyíng

运营

entire chain / end-to-end

quán liàntiáo

全链条

。

the said

gāi

该

partnership

hézuò

合作

aimed at / with the goal of

zhǐzài

旨在

by means of / with the help of

jièzhù

借助

artificial intelligence

rén gōng zhìnéng

人工智能

to shorten / to reduce

suōduǎn

缩短

drug

yàowù

药物

from

cóng

从

research

yánjiū

研究

dào

到

clinical

línchuáng

临床

application / use

yìngyòng

应用

(possessive / modifier particle)

的

cycle / timeline

zhōuqī

周期

。

May 7, 2026 at 5:00 AM

Denmark

Dānmài

丹麦

pharmaceutical

zhìyào

制药

giant / major player

jùtóu

巨头

Novo Nordisk

Nuòhé Nuòdé

诺和诺德

on (date marker)

yú

于

April 14th

4 yuè 14 rì

4月14日

to announce

xuānbù

宣布

with

yǔ

与

OpenAI

to reach / to conclude

dáchéng

达成

comprehensive / full

quánmiàn

全面

strategic

zhànlüè

战略

partnership agreement

hézuò xiéyì

合作协议

。

according to / based on

gēnjù

根据

agreement

xiéyì

协议

，

OpenAI

(possessive / modifier particle)

的

technology

jìshù

技术

will

jiāng

将

(passive voice marker)

bèi

被

comprehensively

quánmiàn

全面

to integrate / to incorporate

zhěnghé

整合

into

zhì

至

Novo Nordisk

Nuòhé Nuòdé

诺和诺德

(possessive / modifier particle)

的

drug

yàowù

药物

research and development

yán fā

研发

、

manufacturing

zhìzào

制造

、

supply chain

gōngyìng liàn

供应链

and / as well as

jí

及

commercial

shāngyè

商业

operations

yùnyíng

运营

each / every

gè

各

link / stage

huánjié

环节

。

partnership / collaboration

hézuò

合作

(possessive / modifier particle)

的

core / central focus

héxīn

核心

goal / objective

mùbiāo

目标

lies in / is centered on

zàiyú

在于

by means of

jièzhù

借助

artificial intelligence

rén gōng zhìnéng

人工智能

to analyze

fēnxī

分析

complex

fùzá

复杂

datasets

shùjù jí

数据集

，

to identify

shíbié

识别

new / novel

xīnxíng

新型

candidate

hòuxuǎn

候选

drugs / compounds

yàowù

药物

，

thereby / so as to

cóng'ér

从而

significantly

dàfú

大幅

to shorten / to reduce

suōduǎn

缩短

R&D

yán fā

研发

cycle / timeline

zhōuqī

周期

。

this time / on this occasion

cǐ cì

此次

collaboration

hézuò

合作

also / furthermore

yì

亦

to cover / to encompass

hángài

涵盖

employees / workforce

yuángōng

员工

artificial intelligence

rén gōng zhìnéng

人工智能

literacy / capability

sùyǎng

素养

training

péixùn

培训

，

planned / scheduled

jìhuà

计划

yú

于

end of 2026

2026 nián dǐ

2026年底

before

qián

前

to complete

wánchéng

完成

full / comprehensive

quánmiàn

全面

deployment / rollout

bùshǔ

部署

。

in terms of background / contextually

bèijǐng shàng

背景上

，

Novo Nordisk

Nuòhé Nuòdé

诺和诺德

is currently facing

zhèng miànlín

正面临

from

láizì

来自

Měiguó

美国

competitor / rival

jìngzhēng duìshǒu

竞争对手

Eli Lilly

Lǐlái

礼来

(possessive / modifier particle)

的

intense / fierce

jīliè

激烈

competition

jìngzhēng

竞争

，

especially / particularly

yóuqí

尤其

manifested in / particularly in

tǐxiàn zài

体现在

body weight

tǐzhòng

体重

management

guǎnlǐ

管理

drugs

yàowù

药物

field / sector

lǐngyù

领域

。

the industry

yèjiè

业界

analysts

fēnxī rénshì

分析人士

to believe / to argue

rènwéi

认为

，

this

cǐ cì

此次

collaboration

hézuò

合作

could help

yǒu zhù yú

有助于

Novo Nordisk

Nuòhé Nuòdé

诺和诺德

zài

在

next-generation

xià yī dài

下一代

weight-loss

jiǎnféi

减肥

drugs

yàowù

药物

R&D

yán fā

研发

in terms of / aspect

fāngmiàn

方面

to regain / to reclaim

chóngshí

重拾

competitive

jìngzhēng

竞争

advantage

yōushì

优势

。

New Words

zhìyào

制药

pharmaceutical

jùtóu

巨头

giant / major player

dáchéng

达成

to reach / to conclude

zhànlüè hézuò

战略合作

strategic partnership

zhěnghé

整合

to integrate

yán fā

研发

research and development

zhōuqī

周期

cycle / timeline

sùyǎng

素养

literacy / capability

jìngzhēng duìshǒu

竞争对手

competitor / rival

yōushì

优势

advantage

News in English

Science & Technology

Novo Nordisk Partners With OpenAI to Accelerate Drug Discovery Using AI

Danish pharmaceutical giant Novo Nordisk and OpenAI announced a strategic partnership on April 14, covering drug discovery, manufacturing, and commercial operations end-to-end. The collaboration aims to use AI to shorten the timeline from research to clinical use.

On April 14th, Danish pharmaceutical giant Novo Nordisk announced a comprehensive strategic partnership agreement with OpenAI. According to the agreement, OpenAI's technology will be comprehensively integrated into Novo Nordisk's drug research and development, manufacturing, supply chain, and commercial operations at every stage.

The core objective of this collaboration is to use artificial intelligence to analyze complex datasets, identify new candidate drugs, and thereby significantly shorten the R&D cycle. The collaboration also includes AI literacy training for employees, with plans for full deployment by the end of 2026.

In context, Novo Nordisk is facing intense competition from US competitor Eli Lilly, particularly in the weight-loss drug field. Industry analysts believe this collaboration could help Novo Nordisk regain competitive advantage in next-generation weight-loss drug development.

New Words

News in English

Novo Nordisk Partners With OpenAI to Accelerate Drug Discovery Using AI

More in Science & Technology